ZOOBIOTIC LIMITED

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

• Turnover

  +5.1%

  £1,759,000 → £1,848,000

• Cash

  -13.6%

  £236,000 → £204,000

• Net assets

  -12.9%

  £3,311,000 → £2,883,000

• Employees

  -7.1%

  28 → 26

• Operating profit

  +43.8%

  -£226,000 → -£127,000

• Profit before tax

  +34.5%

  -£319,000 → -£209,000

• Wages

  +5.4%

  £966,000 → £1,018,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

1. ZOOBIOTIC LIMITED 2004-05-11 → present
2. MC314 LIMITED 2004-03-25 → 2004-05-11

Accounting basis

FRS 102

Reporting scope

Standalone (parent only)

Auditor

Menzies LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.”

Group structure

1. ZOOBIOTIC LIMITED · parent
   1. Biomonde GmbH 100% · Germany · manufacture and distribution of larval debridement therapy
   2. BioMonde (US) LLC 100% · USA · ceased activity in 2019

Significant events

• “During the year ended 31 March 2025, the Company ceased its contract manufacturing dispensing Lysis Buffer.”
• “Dividends of £216,000 (2024: £Nil) were paid in the year.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

4

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.